MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20-85
SponsorFujian Cancer Hospital
About this trial
This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
(1) pathologically confirmed CC, (2) initially treated in our center
Disqualifiers
(1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up
Trial population
cervical cancer patients received definitive radiotherapy with pre-treatment MRI.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
RadiationThe chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: cervical cancer patients with radiotherapy1 intervention
Trial outcomes
Primary outcomes
1
overall survival
the interval from diagnostic day to death or the last follow-up
Time frame
1-36 monthsSecondary outcomes
1
progression-free survival
the interval from diagnostic day to death, the last follow-up, or the onset of regional recurrence or distant metastasis
Time frame
1-36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: